Quince Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

IRulya Therapeutics

13/05/2025 14:19

Quince Therapeutics Inc QNCX.OQ reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -26 cents.  The mean expectation of four analysts for the quarter was for a loss of 23 cents per share. Wall Street expected results to range from -24 cents to -21 cents per share.

Reported revenue was zero​; analysts expected zero.

Quince Therapeutics Inc's reported EPS for the quarter was a loss of 34 cents​.

The company reported a quarterly loss of $15.03 million.

Quince Therapeutics Inc shares had fallen by 22.6% this quarter and lost 44.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 3.4% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Quince Therapeutics Inc is $7.50

This summary was machine generated from LSEG data May 13 at 01:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.23
-0.34
Missed
Dec. 31 2024
-0.17
-0.28
Missed
Sep. 30 2024
-0.21
-0.13
Beat
-0.64